Medovir

Aciclovir, the active ingredient in Medovir, is an antiviral presented as an oral tablet for oral use. It treats herpes simplex virus infections, including cold sores and genital herpes, as well as varicella‑zoster virus infections such as chickenpox and shingles in adults and children.

GNH USA supplies Medovir as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Its distribution network covers Europe, Asia, Africa and the Americas, ensuring timely delivery.

Aciclovir is used to treat viral infections caused by herpes viruses, reducing disease severity and duration.

Herpes simplex virus infections (cold sores, genital herpes): Reduces lesion formation, accelerates healing, lessens pain, and shortens the overall outbreak period. Varicella‑zoster virus infections (chickenpox, shingles): Limits viral replication, shortens rash duration, decreases nerve pain, and lowers the risk of post‑herpetic neuralgia. Herpes labialis: Provides symptomatic relief, faster resolution of oral lesions, and reduces the likelihood of recurrence during the treatment course.

Aciclovir is generally well tolerated, but a range of adverse reactions have been reported.

Common Side Effects: - Nausea - Headache - Abdominal pain or discomfort - Fatigue - Dizziness

Serious or Rare Side Effects: - Acute renal failure or worsening of pre‑existing renal impairment - Severe allergic reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis - Hematologic abnormalities including thrombocytopenia or neutropenia - Hepatic dysfunction with elevated transaminases

When prescribing aciclovir, clinicians should consider several safety and handling precautions.

Renal function: assess baseline renal function and adjust dose in patients with impairment. Hydration status: ensure adequate fluid intake to reduce risk of crystalluria. Concomitant nephrotoxic drugs: monitor closely when used with aminoglycosides or NSAIDs. Immunocompromised patients: watch for delayed viral clearance and potential resistance. Pregnancy and lactation: evaluate risk‑benefit ratio as safety data are limited. Store at ambient temperature below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Aciclovir may interact with other medicines, altering its plasma concentration or toxicity profile.

Major Interactions (Avoid): - Probenecid: decreases renal excretion, markedly increasing aciclovir levels. - Cimetidine: reduces renal clearance, leading to higher systemic exposure. - Co‑administration with other nephrotoxic agents (e.g., aminoglycosides): heightens risk of renal injury.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may affect renal function, requiring monitoring. - Oral contraceptives: aciclovir can slightly reduce efficacy; advise additional contraceptive measures. - Immunosuppressants (e.g., cyclosporine): monitor for increased viral replication or toxicity. - Warfarin: occasional reports of altered INR; check coagulation parameters if combined.